畑地 治 はたじ おさむ 先生

来歴等

略歴

1991年 自治医科大学 卒業
1991年 三重県立総合塩浜病院 研修医（ローテート研修）
1993年 紀南病院 内科 医員
1996年 紀和町立紀和診療 所長
1997年 三重大学 呼吸器内科 医員
1997年 川崎医科大学病理学教室 研修
1998年 紀和町立紀和診療 所長
1999年 三重大学 呼吸器内科 医員
2003年 松阪市民病院 呼吸器科 科長
2022年 松阪市民病院 院長

論文

• 1. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

  Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators.N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21.

• 2. Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial.

  Kataoka K, Nishiyama O, Ogura T, Mori Y, Kozu R, Arizono S, Tsuda T, Tomioka H, Tomii K, Sakamoto K, Ishimoto H, Kagajo M, Ito H, Ichikado K, Sasano H, Eda S, Arita M, Goto Y, Hataji O, Fuke S, Shintani R, Hasegawa H, Ando M, Ogawa T, Shiraishi M, Watanabe F, Nishimura K, Sasaki T, Miyazaki S, Saka H, Kondoh Y; FITNESS study Collaborators.Thorax. 2023 Aug;78(8):784-791. doi: 10.1136/thorax-2022-219792. Epub 2023 Apr 3.

• 3. Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.

  Ikeda M, Okugawa S, Kashiwabara K, Moritoyo T, Kanno Y, Jubishi D, Hashimoto H, Okamoto K, Tsushima K, Uchida Y, Mitsumura T, Igari H, Tsutsumi T, Araoka H, Yatera K, Yamamoto Y, Nakamura Y, Otani A, Yamashita M, Wakimoto Y, Shinohara T, Adachi-Katayama M, Oyabu T, Kanematsu A, Harada S, Takeshita Y, Nakano Y, Miyazaki Y, Sakao S, Saito M, Ogura S, Yamasaki K, Kawasuji H, Hataji O, Inoue JI, Seto Y, Moriya K.Int J Infect Dis. 2023 Mar;128:355-363. doi: 10.1016/j.ijid.2022.12.039. Epub 2023 Jan 4.

• 4. Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL).

  Miura S, Nishio M, Akamatsu H, Goto Y, Hayashi H, Gemma A, Yoshino I, Misumi T, Hata A, Hataji O, Fujita K, Seike M, Yanagitani N, Nishino K, Hara S, Saito R, Mori M, Tsuda T, Iwasawa S, Nakagawa S, Mitsudomi T.JTO Clin Res Rep. 2023 Feb 24;4(3):100484. doi: 10.1016/j.jtocrr.2023.100484. eCollection 2023 Mar.

• 5. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

  Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I.JAMA Oncol. 2023 Dec 21:e235258. doi: 10.1001/jamaoncol.2023.5258. Online ahead of print.

• 6. Risk factors for disease progression in fibrotic hypersensitivity pneumonitis.

  Fujimoto H, Yasuma T, D'Alessandro-Gabazza CN, Gabazza EC, Hataji O, Kobayashi T.Eur Respir J. 2023 Jan 27;61(1):2201706. doi: 10.1183/13993003.01706-2022. Print 2023 Jan.

• 7. Development of a Communication Tool between Patients and Physicians for Recognizing COPD Exacerbations in Japan.

  Jones P, Hataji O, Suzukamo Y, Crawford B, Sakai Y, Ishii T, Sato K, Sasaki E, Hashimoto K, Oga T.COPD. 2023 Dec;20(1):216-223. doi: 10.1080/15412555.2023.2219742.

• 8. Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension.

  Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Gabazza EC, Hataji O, Kobayashi T.Am J Respir Crit Care Med. 2023 Dec 1;208(11):1248. doi: 10.1164/rccm.202308-1347LE.

• 9. Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.

  Ito A, Tarukawa T, Suzuki Y, Sakaguchi T, Ito K, Fujiwara K, Nishii Y, Taguchi O, Yasui H, Takao M, Hataji O.Anticancer Res. 2023 Nov;43(11):5197-5204. doi: 10.21873/anticanres.16721.

• 10. Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.

  Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M.EClinicalMedicine. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303. eCollection 2023 Dec.

• 11. Physical Activity Estimated by the Wearable Device in Lung Disease Patients: Exploratory Analyses of Prospective Observational Study.

  Ito K, Esumi M, Esumi S, Suzuki Y, Sakaguchi T, Fujiwara K, Nishii Y, Yasui H, Taguchi O, Hataji O.J Clin Med. 2023 Jun 30;12(13):4424. doi: 10.3390/jcm12134424.

• 12. Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions.

  Nishii Y, Sakaguchi T, Esumi S, Esumi M, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Yasui H, Ito A, Tarukawa T, Tsuruga T, D'Alessandro-Gabazza CN, Yasuma T, Fujimoto H, Asano F, Gabazza EC, Kobayashi T, Taguchi O, Hataji O.Sci Rep. 2023 Sep 7;13(1):14724. doi: 10.1038/s41598-023-41726-w.

• 13. A case of tracheal stenosis due to anaplastic thyroid carcinoma treated using the stent-in-stent method.

  Sakaguchi T, Ohi M, Nishii Y, Hataji O.Thorac Cancer. 2023 Dec 27. doi: 10.1111/1759-7714.15185. Online ahead of print.

• 14. Refractory response to entrectinib for ROS-1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report.

  Ito K, Nishio M, Fujiwara K, Nishii Y, Ushiro K, Yasui H, Hataji O.Thorac Cancer. 2023 Sep;14(25):2622-2626. doi: 10.1111/1759-7714.15044. Epub 2023 Aug 6.

• 15. Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.

  Sakaguchi T, Iketani A, Esumi S, Esumi M, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Katsuta K, Yasui H, Taguchi O, Hataji O.Sci Rep. 2023 Aug 23;13(1):13759. doi: 10.1038/s41598-023-40271-w.

• 16. Elevated plasma and bile levels of corisin, a microbiota-derived proapoptotic peptide, in patients with severe acute cholangitis.

  Nishiwaki R, Imoto I, Oka S, Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Toda M, Kobayashi T, Osamu H, Fujibe K, Nishikawa K, Hamaguchi T, Sugimasa N, Noji M, Ito Y, Takeuchi K, Cann I, Inoue Y, Kato T, Gabazza EC.Gut Pathog. 2023 Nov 30;15(1):59. doi: 10.1186/s13099-023-00587-4.

• 17. The Potential of Digital Polymerase Chain Reaction for Improving Diagnostic Yield of Nontuberculous Mycobacteria Pulmonary Disease

  Nishii Y, Furuhashi K, Nakamura S, Nishio M, Nakamura Y, Ushiro K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D'Alessandro-Gabazza C, Gabazza EC, Taguchi O, Hataji O Infect Drug Resist. 2021 Dec 1;14:5079-5087.

• 18. Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non-small cell lung cancer.

  Sakaguchi T, Nishii Y, Iketani A, Esumi S, Esumi M, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Katsuta K, Taguchi O, Hataji O. Thorac Cancer. 2022 May;13(10):1449-1456

• 19. Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor

  Sakaguchi T, Kokubo Y, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Taguchi O, Hataji O. Clin Lung Cancer. 2022 May;23(3):e273-e275.

• 20. Good Response of Advanced Thymic Carcinoma With Low PDL1 expression to Chemotherapy Plus Pembrolizumab as Firstline Therapy and to Pembrolizumab as Maintenance Therapy:A Case Report

  Nishii Y, Furuhashi K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D'Alessandro-Gabazza CN, Gabazza EC, Taguchi O, Hataji O. Pharmaceuticals (Basel). 2022 Jul 19;15(7):889.

• 21. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis

  D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara H, Takeshita A, Nishihama K, Okano T, Saiki H, Okano Y, Tomaru A, Fridman D'Alessandro V, Shiraishi M, Mizoguchi A, Ono R, Ohtsuka J, Fukumura M, Nosaka T, Mi X, Shukla D, Kataoka K, Kondoh Y, Hirose M, Arai T, Inoue Y, Yano Y, Mackie RI, Cann I, Gabazza EC. Nat Commun. 2022 Mar 23;13(1):1558.

• 22. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

  Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Lung Cancer. 2022 Jun;168:38-45

• 23. Pseudoprogression of lung large cell neuroendocrine carcinoma resembling pancreatic cancer during durvalumab therapy

  Hattori A, Nishikawa K, Ito K, Tachikawa N, Fujibe K, Tanaka S, Oiwa M, Hataji O. Clin J Gastroenterol. 2022 Jun;15(3):668-672.

• 24. An oldest-old non-small cell lung cancer patient with abscopal effect in a single lesion

  Sakaguchi T, Ito K, Fujiwara K, Nishii Y, Ochiai S, Nomoto Y, Hataji O. Thorac Cancer. 2022 Aug;13(15):2267-2270.

• 25. Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy

  Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Yagi A, D'Alessandro VF, Yasuma T, Furuhashi K, Saiki H, Okano T, Tomaru A, Tanigawa M, D'Alessandro-Gabazza CN, Gabazza EC, Yoshida M, Hataji O, Ibata H, Kobayashi T. Cancers (Basel). 2022 Aug 16;14(16):3953.

• 26. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial

  Nagata K, Horie T, Chohnabayashi N, Jinta T, Tsugitomi R, Shiraki A, Tokioka F, Kadowaki T, Watanabe A, Fukui M, Kitajima T, Sato S, Tsuda T, Kishimoto N, Kita H, Mori Y, Nakayama M, Takahashi K, Tsuboi T, Yoshida M, Hataji O, Fuke S, Kagajo M, Nishine H, Kobayashi H, Nakamura H, Okuda M, Tachibana S, Takata S, Osoreda H, Minami K, Nishimura T, Ishida T, Terada J, Takeuchi N, Kohashi Y, Inoue H, Nakagawa Y, Kikuchi T, Tomii K. Am J Respir Crit Care Med. 2022 Dec 1;206(11):1326-1335.

• 27. A Telemedicine Approach for Monitoring COPD: A Prospective Feasibility and Acceptability Cohort Study

  Shinoda M, Hataji O, Miura M, Kinoshita M, Mizoo A, Tobino K, Soutome T, Nishi T, Ishii T, Miller BE, Tal-Singer R, Tomlinson R, Matsuki T, Jones PW, Shibata Y. Int J Chron Obstruct Pulmon Dis. 2022 Nov 17;17:2931-2944.

• 28. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer

  Sakaguchi T, Iketani A, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Katsuta K, Taguchi O, Hataji O. Thorac Cancer. 2021 Feb;12(4):462-467

• 29. The Potential of Digital Polymerase Chain Reaction for Improving Diagnostic Yield of Nontuberculous Mycobacteria Pulmonary Disease.

  Nishii Y, Furuhashi K, Nakamura S, Nishio M, Nakamura Y, Ushiro K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D'Alessandro-Gabazza C, Gabazza EC, Taguchi O, Hataji O Infect Drug Resist. 2021 Dec 1;14:5079-5087

その他

• 【ラジオ番組】

• レディオキューブFM三重　ゲツモク！番組内　毎週月曜18:22〜18:26

• 「肺、おさむに聴け！〜Radioを聴いてらんらんらん（Lung Lung Lung）〜」放送中

SNS・ブログ等

• その他メディア
  • メールマガジン まぐまぐ！「ドクター畑地の診察室」